![Lazar Mandinov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lazar Mandinov
Corporate Officer/Principal at The European Society of Cardiology
Profile
Lazar Mandinov is a member of The European Society of Cardiology.
He previously worked as a Medical Director at Boston Scientific Corp., Chief Medical Officer at Mitralign, Inc., and Principal at Maine Medical Center Research.
Dr. Mandinov holds a doctorate degree from Medical University Sofia.
Lazar Mandinov active positions
Companies | Position | Start |
---|---|---|
The European Society of Cardiology | Corporate Officer/Principal | - |
Former positions of Lazar Mandinov
Companies | Position | End |
---|---|---|
BOSTON SCIENTIFIC CORPORATION | Chief Tech/Sci/R&D Officer | - |
Maine Medical Center Research | Corporate Officer/Principal | - |
Mitralign, Inc.
![]() Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Chief Tech/Sci/R&D Officer | - |
Training of Lazar Mandinov
Medical University Sofia | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BOSTON SCIENTIFIC CORPORATION | Health Technology |
Private companies | 3 |
---|---|
Mitralign, Inc.
![]() Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
The European Society of Cardiology | |
Maine Medical Center Research |
- Stock Market
- Insiders
- Lazar Mandinov